Welcome to our dedicated page for Evoke Pharma news (Ticker: EVOK), a resource for investors and traders seeking the latest updates and insights on Evoke Pharma stock.
Evoke Pharma, Inc. (formerly NASDAQ: EVOK) generated news primarily as a specialty pharmaceutical company focused on gastrointestinal (GI) disorders and diseases, with an emphasis on diabetic gastroparesis. Company press releases repeatedly describe Evoke’s work around GIMOTI, a metoclopramide nasal spray formulation indicated for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults. News items often explain why a non-oral formulation matters in a condition where delayed gastric emptying can compromise absorption of orally administered medications.
The EVOK news record includes announcements about GIMOTI’s commercial progress, such as updates on net product sales, prescriber adoption and pharmacy access, as well as business updates tied to Evoke’s GI-focused strategy. Several releases detail intellectual property developments, including a Notice of Allowance and the issuance of U.S. Patent No. 12,377,064 covering the use of intranasal metoclopramide in patients with moderate to severe symptoms of gastroparesis, along with plans to list this patent in the FDA’s Orange Book and extend expected exclusivity.
Regulatory and scientific news also appears in the EVOK feed, including communications about real-world safety data on metoclopramide and tardive dyskinesia and presentations at gastroenterology-focused medical meetings. Later news is dominated by transaction-related announcements, including the definitive agreement under which QOL Medical, LLC agreed to acquire Evoke for cash per share, and subsequent updates on the tender offer and merger process.
For readers reviewing EVOK news today, this page functions as an archive of historical developments: commercial milestones for GIMOTI, GI and diabetic gastroparesis–related research communications, patent and Orange Book updates, quarterly financial press releases, and the sequence of events that culminated in Evoke’s acquisition by QOL Medical and the delisting of its common stock from Nasdaq.
Evoke Pharma reported promising results from a recent survey on GIMOTI, its newly launched treatment for diabetic gastroparesis. The survey, conducted in December 2020, involved 104 healthcare practitioners and indicated strong intent to prescribe GIMOTI, with 79% of targeted gastroenterologists and 89% of non-target gastroenterologists expressing positive prescribing trends. Notably, GIMOTI's unique nasal delivery method stands out as an alternative to oral treatments, addressing significant patient needs. The company's leadership expressed optimism over the results, paving the way for enhanced commercial efforts in 2021.
Evoke Pharma, focused on treatments for gastrointestinal diseases, reported its Q3 2020 financial results, highlighting the commercial launch of GIMOTI, a nasal treatment for diabetic gastroparesis, in partnership with EVERSANA.
The net loss was approximately $2.1 million, or $0.08 per share, compared to a loss of $1.6 million, or $0.07 per share, in Q3 2019. Operating expenses rose to $2.1 million driven by commercialization efforts. As of September 30, 2020, cash and equivalents stood at $6.3 million, expected to fund operations into Q2 2021, excluding potential GIMOTI revenue.
Evoke Pharma has announced the commercial launch of Gimoti (metoclopramide) nasal spray, designed specifically for adults suffering from acute and recurrent diabetic gastroparesis. This treatment allows for medication absorption via the nasal mucosa, bypassing gastrointestinal issues common in these patients. Approved by the FDA in June 2020, Gimoti offers a novel alternative to traditional oral medications, which can be ineffective due to unpredictable stomach emptying. With support from EVERSANA, the launch aims to address a significant market need and improve patient outcomes.
Evoke Pharma (EVOK) announced the appointment of Christopher Quesenberry as Chief Commercial Officer for Gimoti, approved by the FDA for treating diabetic gastroparesis. With over 30 years in pharma strategy, Quesenberry will lead the commercialization efforts alongside partner EVERSANA. The collaboration aims to ensure successful market entry and sales for Gimoti, expected to launch in Q4 2020. Evoke's President emphasized the importance of Quesenberry's expertise in executing their commercialization strategy for this critical GI disorder treatment.
Evoke Pharma, Inc. (NASDAQ: EVOK) announced its Q2 2020 financial results, showing a net loss of approximately $7.0 million or $0.28 per share, significantly higher than the $2.1 million net loss in Q2 2019. Research and development expenses surged to $5.8 million due to a $5 million technology acquisition milestone linked to the FDA approval of Gimoti, the first outpatient treatment for diabetic gastroparesis. The company expects to launch Gimoti in Q4 2020 with commercial partner EVERSANA, and reported cash reserves of $8.0 million, sufficient to fund operations into Q2 2021.
Evoke Pharma, Inc. (NASDAQ: EVOK) has commenced the commercial manufacturing of Gimoti™ (metoclopramide) nasal spray with manufacturing partner Patheon. Approved by the FDA on June 19, 2020, Gimoti is intended for adults suffering from diabetic gastroparesis. The company plans to launch sales in Q4 2020 in collaboration with EVERSANA. CEO David Gonyer emphasized the acceleration of pre-commercialization activities, ensuring the timely completion of manufacturing ahead of the launch.
Evoke Pharma (NASDAQ: EVOK) reported approximately $8.0 million in cash as of June 30, 2020, sufficient to fund operations into Q2 2021. The company anticipates launching GIMOTI, the first nasal treatment for diabetic gastroparesis, in Q4 2020 through its partner EVERSANA. This partnership will help mitigate capital investment needs by leveraging EVERSANA's resources for commercialization. GIMOTI addresses a significant unmet need in the treatment of diabetic gastroparesis, which affects millions of patients. Forward-looking statements caution potential risks in achieving growth.
Evoke Pharma, Inc. has received FDA approval for GIMOTI (metoclopramide) nasal spray, the first treatment for acute and recurrent diabetic gastroparesis. This novel therapy promises to address significant patient needs by offering a non-oral option that improves symptom relief. Evoke plans to begin commercial sales in Q4 2020, aided by a $5 million line of credit from EVERSANA. With approximately $4.7 million in cash, the company expects to sustain operations into 2021, potentially enhancing its market position in the gastrointestinal treatment landscape.
Evoke Pharma (NASDAQ: EVOK) has received conditional FDA approval for its proprietary brand name, Gimoti, for a nasal spray targeting symptoms of acute and recurrent diabetic gastroparesis in adult women. The name was developed following FDA guidelines and aims to prevent medication errors. The nasal spray is designed to enhance drug absorption by bypassing the dysfunctional GI tract, which is crucial for patients suffering from this condition. If approved, Gimoti could provide significant treatment options in a market where metoclopramide is currently available only in oral and injectable forms.
Evoke Pharma reported its first quarter 2020 financial results, revealing a net loss of approximately $1.8 million, or $0.07 per share, an improvement from a loss of $2.0 million, or $0.11 per share, in Q1 2019. R&D expenses decreased to $0.5 million, while general and administrative expenses rose slightly to $1.3 million. Cash and cash equivalents stood at around $4.1 million, expected to last until Q3 2020. The FDA's PDUFA date for Gimoti is June 19, 2020, which is crucial for advancing their commercialization strategy with Eversana Life Sciences.
FAQ
What is the current stock price of Evoke Pharma (EVOK)?
What is the market cap of Evoke Pharma (EVOK)?
